Company: SMNR
Filing Date: 2025-08-12
Form Type: S-4/A
Source: 0001193125-25-178821
Chunk: 821

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-4/A
Chunk 821
---
2023 |     |              | 160,000,000 |     |        | 2 |     |            | 72,598 |     |             | (110,694 | ) |     |               | (38,094 | ) |
| Net loss                   |     |              |           — |     |        | — |     |            |      — |     |             | (4,690   | ) |     |               | (4,690  | ) |
| Balance, December 31, 2024 |     |              | 160,000,000 |     | $      | 2 |     | $          | 72,598 |     | $           | (115,384 | ) |     | $             | (42,784 | ) |

See accompanying notes to financial statements F-68

#### SEMNUR PHARMACEUTICALS, INC.STATEMENTS OF CASH FLOWS(In thousands)Years Ended December 31,20242023Operating activitiesNet loss$(4,690)$(3,261)Adjustments to reconcile net loss to net cash used for operating activities:Stock-based compensation660840Changes in operating assets and liabilities:Prepaid expenses—43Accrued expenses(861)701Net cash used for operating activities(4,891)(1,677)Financing activitiesProceeds from related party loans10,8721,661Payments of deferred offering costs(5,981)—Net cash provided by financing activities4,8911,661Net change in cash and cash equivalents—(16)Cash and cash equivalents at beginning of period1228Cash and cash equivalents at end of period$12$12See accompanying notes to financial statementsF-69
<div align='center'>**SEMNUR PHARMACEUTICALS, INC.

NOTES TO FINANCIAL STATEMENTS**</div>

**Note 1. Nature of Operations and Basis of Presentation

Organization and Principal Activities

Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) was formed in 2013 and became a wholly owned subsidiary of Scilex Holding Company (“Scilex”) in 2019. The Company is a late clinical stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. The Company is currently developing one product candidate, SP-102 (10 mg, dexamethasone sodium phosphate viscous gel), a novel, viscous gel formulation of a widely used